Life Technologies 400 base-pair Sequencing Kit for Ion PGM™ Sequencer delivers reads 60 percent longer than comparable high

Life Technologies 400 base-pair Sequencing Kit for Ion PGM™ Sequencer delivers
 reads 60 percent longer than comparable high-throughput benchtop sequencers

Ion 400 base-pair kit enables world-class bacterial assembly, HLA and 16S
ribosomal gene sequencing, capping off another year of market-leading

PR Newswire

CARLSBAD, Calif., Dec. 19, 2012

CARLSBAD, Calif., Dec. 19, 2012 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) announced today a new 400 base-pair sequencing kit for the Ion
PGM™ Sequencer. The kit produces reads 60 percent longer than comparable
high-throughput benchtop sequencers, generating more complete bacterial de
novo assemblies with longer contiguous sequences. To see a video about the 400
bp kit and other new products, click here.

"Ion Torrent's long, accurate 400 base pair reads enable excellent bacterial
de novo assembly," said Professor Dag Harmsen, Head of Research, Department of
Periodontology, University of Muenster, who used the Ion PGM™ Sequencer to
help crack the E. coli outbreak in Germany in 2011."Paired-end sequencing is
not required to get the best results."

The Ion PGM™ sequencing 400 kit is ideal for applications that require
capturing all the genetic variation in a long exon on a single read. For
instance, long reads are critical for researchers trying to interpret genetic
data from human leukocyte antigen (HLA) genes or 16S ribosomal genes.

"Sequencing the V1-V2 region of the bacterial 16s rRNA gene would not be
possible on the Ion PGM™ without the longer 400 base pair reads," said Dr.
George Watts, Research Assistant Professor and Co-Director, Genomic Shared
Service, University of Arizona Cancer Center. "Using 400 base pair reads
allows us to increase the information density of the amplicons and better
define the constituents of complex microbial populations."

Ion Torrent continues to see rapid increases in accuracy on its Ion PGM™ and
Ion Proton™ Sequencers as a result of consistent improvements in its
algorithms. The new Torrent Suite v3.4 incorporates algorithmic improvements
in both raw accuracy and consensus variant calling. These improvements enable
both the Ion PGM™ and Ion Proton™ semiconductor sequencing platforms to
routinely achieve greater than 99.996 percent consensus accuracy.

Life Technologies is also introducing two additional products, capping a year
of extraordinary innovation that made the Ion PGM™ Sequencer the
fastest-selling sequencer in the world: 

  oThe Ion Total RNA-Seq Kit for AB Library Builder™, which is designed to
    make cDNA library preparation for the semiconductor sequencing simple,
    fast and flexible. The Ion Total RNA-Seq Library Kit for AB Library
    Builder™ System enables the construction of cDNA libraries from both whole
    transcriptome and purified small RNA (miRNA) populations, allowing
    researchers to analyze all types of RNA molecules.
  oThe Thermo Scientific® MuSeek™ Library Preparation Kit, provides a fast
    and simple transposon-based method for preparing high-quality genomic DNA
    libraries for the Ion PGM™ Sequencer. The kit utilizes MuA transposase
    enzyme for fragmentation and simultaneous tagging of the target DNA,
    eliminating the need for separate shearing and adaptor ligation steps.
    Life Technologies is excited to offer this new kit, which enables library
    construction in as little as 90 minutes, resulting in significant savings
    in time and cost.

The Ion Torrent products discussed in this press release are for Research Use
Only, not for use in diagnostic procedures.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum, with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied
Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes®, Novex®, and
TaqMan®. Life Technologies employs approximately 10,400 people and upholds its
ongoing commitment to innovation with more than 4,000 patents and exclusive
licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Media Contacts:
Wes Conard
Life Technologies Corporation

SOURCE Life Technologies

Press spacebar to pause and continue. Press esc to stop.